Anavex Life Sciences Corp. (AVXL)
| Market Cap | 137.19M -81.8% |
| Revenue (ttm) | n/a |
| Net Income | -13.02M |
| EPS | -0.14 |
| Shares Out | 92.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,768,350 |
| Open | 1.500 |
| Previous Close | 1.490 |
| Day's Range | 1.470 - 1.540 |
| 52-Week Range | 1.440 - 9.500 |
| Beta | 1.17 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia;... [Read more]
Financial Performance
Financial StatementsNews
Anavex receives FDA clearance for Anavex2-73 IND application
Anavex (AVXL) announced that it has received notification from the FDA that the company may proceed with its planned clinical study under its investigational new drug application, or IND, for…
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcam...
Kaplan Fox Advises Anavex Life Sciences Corp. (AVXL) Investors to Act Before the Lead Plaintiff Deadline on November 30, 2026
New York, New York--(Newsfile Corp. - October 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company"...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL
The Red Flags: What Insiders Allegedly Knew Before Shareholders Did. Anavex now says its Board reviews and executive certifications could operate on incomplete information, and it has told investors t...
Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (AVXL): Grabar Law Office Investigates Claims on Your Behalf
Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Anavex Life Sciences Corp...
Anavex says stockholders elect all company director nominees
Anavex (AVXL) Life Sciences announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders, Anavex stockholders have vo...
Anavex Stockholders Elect All of the Company's Director Nominees at 2026 Annual Meeting
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central ...
PVG Asset Management announces plan for first 100 days at Anavex
PVG Asset Management, a stockholder of 337,663 shares of Anavex (AVXL) Life Sciences, announced its plan following its anticipated success in the Company’s upcoming proxy vote. “PVG management is opti...
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders – -- Believes Anavex Needs New Leadership...
PVG says Glass Lewis recommends Anavex shareholders vote for two nominees
PVG Asset Management, a stockholder of 337,663 shares of Anavex (AVXL) Life Sciences Corp., announced that independent proxy advisory firm Glass Lewis & Co. recommended that AVXL stockholders vote the...
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management's Call for Change
-- Proxy advisor recommends voting “ FOR” two of PVG's director nominees and “AGAINST” two incumbent director nominees including the board's current chair on the GOLD Universal Proxy Card –
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 15, 2026, providing details for shareholder voting and corporate governance matters.
PVG Asset Management Believes ISS Acknowledges Anavex's Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board's nominees –
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex's Highly Qualified Director Nominees
ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS' Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOB...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
CENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ: AVXL) ("Anavex" or the "Company"), today announced that i...
Anavex Life Sciences Transcript: Status update
Regained Nasdaq compliance and addressed internal control weaknesses, with a remediation plan underway. Focused resources on advancing blarcamesine for Alzheimer's, Rett syndrome, and Fragile X syndrome, while pausing other programs. Committed to transparency and regular updates.
PVG says Anavex board of directors ‘should be replaced’
The firm said,” PVG Asset Management, a stockholder of Anavex (AVXL) Life Sciences, believes the Anavex Board of Directors should be replaced and an experienced CEO should be hired. The…
PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)
CENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (Nasdaq: AVXL "Anavex" or the "Company"), believes the Anavex Boar...
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 8, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
PVG calls for ‘meaningful board refreshment’ at Anavex
PVG Asset Management Corp., a stockholder of Anavex (AVXL) Life Sciences Corp., sent an open letter to the stockholders of Anavex. In its letter, PVG details why it is calling…
Anavex regains compliance with exchange filing rules
Anavex (AVXL) Life Sciences announced that it has received confirmation from the Nasdaq Stock Market that the company has regained compliance with periodic filing requirements. The determination follo...
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...